Wells Fargo & Company has filed a preliminary pricing supplement for its Medium-Term Notes, Series AA, as part of its strategy to raise capital through fixed-rate callable notes. This move is significant as it underscores the company's ongoing efforts to enhance its financial stability in a competitive banking environment.
The notes will have a term of 20 years and will be subject to redemption by Wells Fargo after three years from issuance. They will pay interest semi-annually at a fixed rate of 6.25% per annum. The notes are designed to be held to maturity and will not be listed on any exchange.
Background
Wells Fargo & Company, classified under the Standard Industrial Classification (SIC) code 6021, operates as a national commercial bank. The company is listed on the New York Stock Exchange under the ticker symbol WFC. Wells Fargo has a long history in the banking sector and is recognized as one of the largest financial institutions in the United States.
What the Filing Says
The filing, dated October 29, 2026, indicates that the notes will be issued at an original offering price of $1,000 per note, with variations for eligible institutional investors. The filing states, "The notes pay interest semi-annually at a fixed per annum rate, as set forth below." This highlights the structured nature of the investment and the interest payment schedule.
Impact
This issuance may affect various stakeholders, including investors seeking fixed-income opportunities and competitors within the national commercial banking sector. The notes' structure and interest rate may attract investors looking for stable returns, particularly in a fluctuating economic environment.
What's Next
The filing does not specify what happens next, but typically, further details regarding the offering and its reception will follow as the pricing date approaches on November 10, 2026.
Read Next
Workers United Files to Sell $8.4 Million in Amalgamated Stock
Carvana Co. files to sell 10 million shares of stock
Platford Giles Richard to Sell 55,617 Takeda Shares
Takeda's Teresa Bitetti to Sell 46,609 Shares Amid Tax Obligations
Kiniksa Pharmaceuticals reports significant stock sale by officer
Moat Ross to Sell Over 103,000 Shares of Kiniksa Pharmaceuticals










